Induction of WT1-specific human CD81 T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice

Blood

Volumn 127, Issue 6, 2016, Pages 722-734

  Najima, Yuho ^a   Tomizawa Murasawa, Mariko ^a   Saito, Yoriko ^a   Watanabe, Takashi ^a   Ono, Rintaro ^a   Ochi, Toshiki ^b   Suzuki, Nahoko ^a   Fujiwara, Hiroshi ^b   Ohara, Osamu ^a   Shultz, Leonard D ^c   Yasukawa, Masaki ^b   Ishikawa, Fumihiko ^a  

^a Institute of Physical and Chemical Research   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; GRANZYME A; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA DR ANTIGEN; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR ALPHA; WT1 PROTEIN; HLA-A*02:01 ANTIGEN; HLA-A*24:02 ANTIGEN; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; WT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENGRAFTMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THYMUS; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; K-562 CELL LINE; METABOLISM; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; SCID MOUSE; TRANSGENIC MOUSE;

ANIMALS; ANIMALS, NEWBORN; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; FEMALE; HEMATOPOIETIC STEM CELLS; HLA-A2 ANTIGEN; HLA-A24 ANTIGEN; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; K562 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 84959333007     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-10-604777     Document Type: Article

References (52)

1. Finn OJ. Cancer immunology. N Engl J Med. 2008;358(25):2704-2715.
2. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer. 2010;10(3):213-221.
3. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4): 265-277.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909-915.
5. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: Are we there yet? Immunol Rev. 2011;239(1):27-44.
6. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-2127.
7. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
8. Rosenberg SA. Raising the bar: The curative potential of human cancer immunotherapy. Sci Transl Med. 2012;4(127):127ps8.
9. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269-281.
10. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-733.
11. Brentjens RJ, Rivi ere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
12. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptortransduced T cells. Blood. 2012;119(12): 2709-2720.
13. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16): 1509-1518.
14. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18(4):666-668.
15. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18(4):843-851.
16. Rezvani K, Yong AS, Mielke S, et al. Leukemiaassociated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236-242.
17. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26): 6541-6548.
18. Bocchia M, Gentili S, Abruzzese E, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet. 2005;365(9460):657-662.
19. Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011; 29(20):2787-2794.
20. Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010;2(17):17ra9.
21. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-5337.
22. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101(38):13885-13890.
23. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA. 2010; 107(31):13824-13829.
24. Shultz LD, Saito Y, Najima Y, et al. Generation of functional human T-cell subsets with HLArestricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci USA. 2010; 107(29):13022-13027.
25. Demachi-Okamura A, Torikai H, Akatsuka Y, Miyoshi H, Yoshimori T, Kuzushima K. Autophagy creates a CTL epitope that mimics tumorassociated antigens. PLoS One. 2012;7(10): e47126.
26. Ellis J, Steiner N, Kosman C, et al. Seventeen more novel HLA-A locus alleles. Tissue Antigens. 2000;55(4):369-373.
27. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens. 1996;47(2):93-101.
28. Strowig T, Gurer C, Ploss A, et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 2009;206(6):1423-1434.
29. Poulin LF, Salio M, Griessinger E, et al. Characterization of human DNGR-11 BDCA31 leukocytes as putative equivalents of mouse CD8alpha1 dendritic cells. J Exp Med. 2010; 207(6):1261-1271.
30. Jongbloed SL, Kassianos AJ, McDonald KJ, et al. Human CD1411 (BDCA-3)1 dendritic cells (DCs) represent a unique myeloid DC subset that crosspresents necrotic cell antigens. J Exp Med. 2010; 207(6):1247-1260.
31. Crozat K, Guiton R, Contreras V, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha1 dendritic cells. J Exp Med. 2010; 207(6):1283-1292.
32. Bachem A, Guttler S, Hartung E, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c1CD1411 cells as homologues of mouse CD81 dendritic cells. J Exp Med. 2010;207(6):1273-1281.
33. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLRbased immune adjuvants. Vaccine. 2011;29(17): 3341-3355.
34. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor selfantigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18(23): 6497-6508.
35. Klebanoff CA, Gattinoni L, Restifo NP. CD81 T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211(1): 214-224.
36. Bendle GM, Linnemann C, Hooijkaas AI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010; 16(5):565-570.
37. Okamoto S, Mineno J, Ikeda H, et al. Improved expression and reactivity of transduced tumorspecific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009; 69(23):9003-9011.
38. Ochi T, Fujiwara H, Okamoto S, et al. Novel adoptive T-cell immunotherapy using a WT1- specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood. 2011;118(6): 1495-1503.
39. Yang L, Baltimore D. Long-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells. Proc Natl Acad Sci USA. 2005;102(12):4518-4523.
40. Vatakis DN, Koya RC, Nixon CC, et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci USA. 2011;108(51):E1408-E1416.
41. Vatakis DN, Arumugam B, Kim SG, Bristol G, Yang O, Zack JA. Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther. 2013;21(5):1055-1063.
42. Giannoni F, Hardee CL, Wherley J, et al. Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells. Mol Ther. 2013;21(5):1044-1054.
43. Melkus MW, Estes JD, Padgett-Thomas A, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006;12(11):1316-1322.
44. Hastie ND. Life, sex, and WT1 isoforms-three amino acids can make all the difference. Cell. 2001;106(4):391-394.
45. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991;5(8):1345-1356.
46. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1): 35-42.
47. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994;91(9):3515-3519.
48. Wiesel M, Oxenius A. From crucial to negligible: functional CD8? T-cell responses and their dependence on CD4? T-cell help. Eur J Immunol. 2012;42(5):1080-1088.
49. Cilloni D, Renneville A, Hermitte F, et al. Realtime quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol. 2009; 27(31):5195-5201.
50. Lange T, Hubmann M, Burkhardt R, et al. Monitoring of WT1 expression in PB and CD34(1) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia. 2011;25(3):498-505.
51. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290-1297.
52. Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671-684.